Cargando…
Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics
BACKGROUND: Medication adherence is the main determinant of effective management of type 2 diabetes, yet there is no gold standard method available to screen patients with high-risk non-adherence. Developing machine learning models to predict high-risk non-adherence in patients with T2D could optimi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714465/ https://www.ncbi.nlm.nih.gov/pubmed/36466490 http://dx.doi.org/10.3389/fpubh.2022.1000622 |
_version_ | 1784842233131827200 |
---|---|
author | Li, Mengting Lu, Xiangyu Yang, HengBo Yuan, Rong Yang, Yong Tong, Rongsheng Wu, Xingwei |
author_facet | Li, Mengting Lu, Xiangyu Yang, HengBo Yuan, Rong Yang, Yong Tong, Rongsheng Wu, Xingwei |
author_sort | Li, Mengting |
collection | PubMed |
description | BACKGROUND: Medication adherence is the main determinant of effective management of type 2 diabetes, yet there is no gold standard method available to screen patients with high-risk non-adherence. Developing machine learning models to predict high-risk non-adherence in patients with T2D could optimize management. METHODS: This cross-sectional study was carried out on patients with T2D at the Sichuan Provincial People's Hospital from April 2018 to December 2019 who were examined for HbA1c on the day of the survey. Demographic and clinical characteristics were extracted from the questionnaire and electronic medical records. The sample was randomly divided into a training dataset and a test dataset with a radio of 8:2 after data preprocessing. Four imputing methods, five sampling methods, three screening methods, and 18 machine learning algorithms were used to groom data and develop and validate models. Bootstrapping was performed to generate the validation set for external validation and univariate analysis. Models were compared on the basis of predictive performance metrics. Finally, we validated the sample size on the best model. RESULTS: This study included 980 patients with T2D, of whom 184 (18.8%) were defined as medication non-adherence. The results indicated that the model used modified random forest as the imputation method, random under sampler as the sampling method, Boruta as the feature screening method and the ensemble algorithms and had the best performance. The area under the receiver operating characteristic curve (AUC), F1 score, and area under the precision-recall curve (AUPRC) of the best model, among a total of 1,080 trained models, were 0.8369, 0.7912, and 0.9574, respectively. Age, present fasting blood glucose (FBG) values, present HbA1c values, present random blood glucose (RBG) values, and body mass index (BMI) were the most significant contributors associated with risks of medication adherence. CONCLUSION: We found that machine learning methods could be used to predict the risk of non-adherence in patients with T2D. The proposed model was well performed to identify patients with T2D with non-adherence and could help improve individualized T2D management. |
format | Online Article Text |
id | pubmed-9714465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97144652022-12-02 Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics Li, Mengting Lu, Xiangyu Yang, HengBo Yuan, Rong Yang, Yong Tong, Rongsheng Wu, Xingwei Front Public Health Public Health BACKGROUND: Medication adherence is the main determinant of effective management of type 2 diabetes, yet there is no gold standard method available to screen patients with high-risk non-adherence. Developing machine learning models to predict high-risk non-adherence in patients with T2D could optimize management. METHODS: This cross-sectional study was carried out on patients with T2D at the Sichuan Provincial People's Hospital from April 2018 to December 2019 who were examined for HbA1c on the day of the survey. Demographic and clinical characteristics were extracted from the questionnaire and electronic medical records. The sample was randomly divided into a training dataset and a test dataset with a radio of 8:2 after data preprocessing. Four imputing methods, five sampling methods, three screening methods, and 18 machine learning algorithms were used to groom data and develop and validate models. Bootstrapping was performed to generate the validation set for external validation and univariate analysis. Models were compared on the basis of predictive performance metrics. Finally, we validated the sample size on the best model. RESULTS: This study included 980 patients with T2D, of whom 184 (18.8%) were defined as medication non-adherence. The results indicated that the model used modified random forest as the imputation method, random under sampler as the sampling method, Boruta as the feature screening method and the ensemble algorithms and had the best performance. The area under the receiver operating characteristic curve (AUC), F1 score, and area under the precision-recall curve (AUPRC) of the best model, among a total of 1,080 trained models, were 0.8369, 0.7912, and 0.9574, respectively. Age, present fasting blood glucose (FBG) values, present HbA1c values, present random blood glucose (RBG) values, and body mass index (BMI) were the most significant contributors associated with risks of medication adherence. CONCLUSION: We found that machine learning methods could be used to predict the risk of non-adherence in patients with T2D. The proposed model was well performed to identify patients with T2D with non-adherence and could help improve individualized T2D management. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9714465/ /pubmed/36466490 http://dx.doi.org/10.3389/fpubh.2022.1000622 Text en Copyright © 2022 Li, Lu, Yang, Yuan, Yang, Tong and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Li, Mengting Lu, Xiangyu Yang, HengBo Yuan, Rong Yang, Yong Tong, Rongsheng Wu, Xingwei Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics |
title | Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics |
title_full | Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics |
title_fullStr | Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics |
title_full_unstemmed | Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics |
title_short | Development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics |
title_sort | development and assessment of novel machine learning models to predict medication non-adherence risks in type 2 diabetics |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714465/ https://www.ncbi.nlm.nih.gov/pubmed/36466490 http://dx.doi.org/10.3389/fpubh.2022.1000622 |
work_keys_str_mv | AT limengting developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics AT luxiangyu developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics AT yanghengbo developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics AT yuanrong developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics AT yangyong developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics AT tongrongsheng developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics AT wuxingwei developmentandassessmentofnovelmachinelearningmodelstopredictmedicationnonadherencerisksintype2diabetics |